08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Mylan deal

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Sanofi deal

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant...
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Sanofi sells dermatology business to Valeant

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired the Dermik dermatology unit from Sanofi (Euronext:SAN; NYSE:SNY) for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had...
08:00 , Oct 31, 2005 |  BC Week In Review  |  Clinical News

BenzaClin dermatology data

In an evaluator-blind trial in 132 patients, BenzaClin (Group 1) significantly reduced inflammatory lesions at week 2 compared with 0.025% tretinoin plus 1% clindamycin (Group 2) and BenzaClin plus 0.025% tretinoin and 1% clindamycin (Group...
07:00 , May 24, 2004 |  BC Week In Review  |  Company News

Aventis sales and marketing update

AVE subsidiary Dermik Laboratories (Montreal, Quebec) launched its BenzaClin topical clindamycin in Canada to treat moderate acne. The product already is marketed in the U.S. Aventis S.A. (AVE), Strasbourg, France   Business: Dermatology   ...